信用評等機構
CRO（合約研究組織）板塊專注醫藥研發外包，涵蓋藥物發現、臨床前研究、臨床試驗營運、生物統計與藥政註冊等核心賽道，助力創新藥降本增效。該板塊總市值為 298.49 billion HKD，24h 漲跌幅 +0.03%，9 檔中，7 檔上漲 (77.78%)，2 檔下跌 (22.22%)。領漲個股為 維亞生物 (01873)，24h 漲幅為 +5.69%。基調偏強，且領先股的廣度與品質正在改善。短期以交易領先股為主；配合財報節奏與利率走勢，選擇性地加碼。
名稱 | 最新價 | 漲跌幅 | 最新價 / 漲跌幅 | 走勢圖 | 價格區間 | 操作 |
|---|---|---|---|---|---|---|
 藥明生物02269 | HK$38.66$159.49 | -1.12%-$1.81 | HK$38.66 -1.12% | $158.75$163.62 | ||
 藥明康德02359 | HK$157.0$647.7 | -0.25%-$1.6 | HK$157.0 -0.25% | $645.2$659.2 | ||
 金斯瑞生物科技01548 | HK$16.82$69.39 | +4.47%+$2.97 | HK$16.82 +4.47% | $66.29$69.39 | ||
 昭衍新藥06127 | HK$25.02$103.22 | +2.28%+$2.31 | HK$25.02 +2.28% | $100.91$107.76 | ||
 康龍化成03759 | HK$23.76$98.02 | +0.42%+$0.41 | HK$23.76 +0.42% | $96.78$99.67 | ||
 凱萊英06821 | HK$118.20$487.65 | +2.33%+$11.13 | HK$118.20 +2.33% | $476.51$503.74 | ||
 泰格醫藥03347 | HK$37.84$156.11 | +1.72%+$2.64 | HK$37.84 +1.72% | $152.48$158.01 | ||
 維亞生物01873 | HK$1.30$5.36 | +5.69%+$0.28 | HK$1.30 +5.69% | $5.07$5.40 | ||
 FANGDA HOLDING01521 | HK$1.15$4.74 | +0.87%+$0.04 | HK$1.15 +0.87% | $4.41$4.78 |